WO1994001547A3 - A method for generation of antibodies to cell surface molecules - Google Patents

A method for generation of antibodies to cell surface molecules Download PDF

Info

Publication number
WO1994001547A3
WO1994001547A3 PCT/US1993/006432 US9306432W WO9401547A3 WO 1994001547 A3 WO1994001547 A3 WO 1994001547A3 US 9306432 W US9306432 W US 9306432W WO 9401547 A3 WO9401547 A3 WO 9401547A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
antibody
cells
treat
insect cells
Prior art date
Application number
PCT/US1993/006432
Other languages
French (fr)
Other versions
WO1994001547A2 (en
Inventor
Boer Mark De
Leah B Conroy
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Priority to DK99104709T priority Critical patent/DK0945465T3/en
Priority to JP50350794A priority patent/JP3514759B2/en
Priority to AT93917032T priority patent/ATE258595T1/en
Priority to EP93917032A priority patent/EP0651797B1/en
Priority to DE69333403T priority patent/DE69333403T2/en
Priority to CA2125472A priority patent/CA2125472C/en
Publication of WO1994001547A2 publication Critical patent/WO1994001547A2/en
Publication of WO1994001547A3 publication Critical patent/WO1994001547A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Abstract

The present invention relates to a method of generating antibodies directed against cell surface antigens and it uses recombinant insect cells as immunogens. The insect cells have been transfected with coding regions for a molecule containing a cell surface antigen and these antigens are expressed on the surface of the insect cells. Host animals are immunized with these transfected insect cells to generate antibodies directed against the cell surface antigen. Antibody-producing cells from the host animal are used to generate monoclonal antibody-producing hybridoma cells. Sera and hybridoma supernatants can be tested for the presence of antibodies against the surface antigen, using the transfected cells in a screening assay. Specific antibodies that have been generated by the present method are anti-B7 and anti-CD40 antibodies and they can be used to prevent or treat an antibody-mediated or immune system disease in a patient. The anti-B7 antibodies can be used to cause T cell anergy, treat allograft transplant rejection, treat graft versus host disease, and prevent or treat rheumatoid arthritis. An immunosuppressive agent may be co-administered with the antibody. The anti-CD40 antibodies which bind to the CD40 antigen can be used to prevent the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.
PCT/US1993/006432 1992-07-09 1993-07-08 A method for generation of antibodies to cell surface molecules WO1994001547A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK99104709T DK0945465T3 (en) 1992-07-09 1993-07-08 Antagonistic monoclonal antibodies to human CD40
JP50350794A JP3514759B2 (en) 1992-07-09 1993-07-08 Methods for producing antibodies against cell surface molecules
AT93917032T ATE258595T1 (en) 1992-07-09 1993-07-08 METHOD FOR GENERATING ANTIBODIES AGAINST CELL SURFACE MOLECULES
EP93917032A EP0651797B1 (en) 1992-07-09 1993-07-08 A method for generation of antibodies to cell surface molecules
DE69333403T DE69333403T2 (en) 1992-07-09 1993-07-08 METHOD FOR PRODUCING ANTIBODIES AGAINST CELL SURFACE MOLECULES
CA2125472A CA2125472C (en) 1992-07-09 1993-07-08 A method for generation of antibodies to cell surface molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/910,222 1992-07-09
US07/910,222 US5397703A (en) 1992-07-09 1992-07-09 Method for generation of antibodies to cell surface molecules

Publications (2)

Publication Number Publication Date
WO1994001547A2 WO1994001547A2 (en) 1994-01-20
WO1994001547A3 true WO1994001547A3 (en) 1994-03-31

Family

ID=25428487

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/006432 WO1994001547A2 (en) 1992-07-09 1993-07-08 A method for generation of antibodies to cell surface molecules

Country Status (5)

Country Link
US (9) US5397703A (en)
JP (8) JP3514759B2 (en)
CA (1) CA2125472C (en)
PT (1) PT945465E (en)
WO (1) WO1994001547A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828396B2 (en) 2010-11-15 2014-09-09 Novartis Ag Silent Fc variants of anti-CD40 antibodies

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
US6084067A (en) * 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
JP3675819B2 (en) * 1993-10-01 2005-07-27 イミュネックス・コーポレーション Antibody against CD40
US6461867B1 (en) * 1995-03-08 2002-10-08 The Scripps Research Institute Synthetic antigen presenting matrix
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
EP0831917A2 (en) * 1995-06-07 1998-04-01 Innogenetics N.V. Immunotoxins specific for cd80 and cd86 expressing cells
US5877021A (en) 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
DE69731836T2 (en) * 1996-07-23 2005-12-01 Pangenetics B.V. INDUCTION OF T CELL TOLERANCE USING A SOLUBLE MOLECULAR THAT CAN CREATE TWO COSTIMULATION PATHS AT THE SAME TIME
US6328969B1 (en) 1996-12-10 2001-12-11 Sloan-Kettering Institute For Cancer Research Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen
US7556805B2 (en) * 1996-12-10 2009-07-07 Sloan-Kettering Inststute for Cancer Research and The Animal Medical Center Compositions for treatment of melanoma and method of using same
WO1998030241A1 (en) * 1997-01-10 1998-07-16 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
US8021666B2 (en) * 1997-02-18 2011-09-20 Sloan-Kettering Institute For Cancer Research Method and compositions for stimulation of an immune response to CD20 using a xenogeneic CD20 antigen
US20100068263A1 (en) * 1997-02-18 2010-03-18 Sloan-Kettering Institute For Cancer Research Method and Compositions for Stimulation of an Immune Response to TRP2 using a Xenogeneic TRP2 Antigen
US20020155093A1 (en) * 1997-02-18 2002-10-24 Houghton Alan N. Method for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
US20100068262A1 (en) * 1997-02-18 2010-03-18 Sloan-Kettering Institute For Cancer Research Method and Compositions for Stimulation of an Immune Response to PSMA using a Xenogeneic PSMA Antigen
US20100068216A1 (en) * 1997-02-18 2010-03-18 Sloan-Kettering Institute For Cancer Research Method and Compositions for Stimulation of an Immune Response to gp100 using a Xenogeneic gp100 Antigen
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20050031611A1 (en) * 1998-05-08 2005-02-10 Beth Israel Deaconess Medical Center Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
CN1352686A (en) 1998-12-14 2002-06-05 遗传学院有限公司 Cytokine receptor chain
JP2002533118A (en) * 1998-12-29 2002-10-08 ユニバーシティ オブ バーモント アンド ステイト アグリカルチャー カレッジ Use of CD40 engagement to modify T cell receptor use
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
HUP0301208A2 (en) * 1999-02-12 2003-08-28 Genetics Institute, Llc Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
EP2039368A3 (en) 1999-04-30 2009-04-01 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
KR20020027311A (en) * 1999-05-07 2002-04-13 제넨테크, 인크. Treatment of Autoimmune Diseases with Antagonists Which Bind to B Cell Surface Markers
WO2000072882A1 (en) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Preventives for idiopathic thrombocytopenic purpura
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE50003454D1 (en) * 1999-06-12 2003-10-02 Bitop Ag PROTEIN CONTAINING PHARMACEUTICAL PREPARATION
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
IL147017A0 (en) * 1999-06-25 2002-08-14 Genentech Inc TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BR0013201A (en) * 1999-07-12 2002-04-30 Genentech Inc Method of blocking an immune response to an external antigen in mammals through the use of an antagonist that binds to cd20, method of treating mammals, method of treating a disease of graft versus host or host versus graft in mammals, method of numbness of mammals awaiting transplantation and industrialized article
WO2001024823A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Cd40 antagonist for treating psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2001066141A1 (en) * 2000-03-06 2001-09-13 Eisai Co., Ltd. Remedies and preventives for antiphospholipid antibody syndrome
AU2001249182A1 (en) * 2000-03-14 2001-09-24 Genetics Institute Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
WO2001077342A1 (en) 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
CA2405632A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceutical Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2001083781A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
CN101711868A (en) 2000-05-19 2010-05-26 杰南技术公司 Gene detection assay for improving the likelihood of an effective response to a ErbB antibody cancer therapy
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
KR100895552B1 (en) 2000-07-03 2009-04-29 브리스톨-마이어스스퀴브컴파니 Methods for Treating Rheumatic Diseases Using a Soluble CTLA4 Molecule
JP4271440B2 (en) 2000-10-02 2009-06-03 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Human anti-CD40 antibody
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
CA2438754C (en) * 2001-02-20 2014-10-07 Ortho-Mcneil Pharmaceutical, Inc. A cell therapy method for the treatment of tumors
JP4679035B2 (en) * 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド Combination therapy
CN101508734A (en) * 2001-04-27 2009-08-19 协和发酵麒麟株式会社 Anti-CD40 monoclonal antibody
PT1397153E (en) 2001-05-23 2008-06-12 Bristol Myers Squibb Co Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
WO2003004625A1 (en) * 2001-07-02 2003-01-16 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Methods of generating human cd4+ th2 cells and uses thereof
US7718196B2 (en) * 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
CA2451680C (en) 2001-07-03 2011-04-19 Genentech, Inc. Human dr4 antibodies and uses thereof
US20030086940A1 (en) * 2001-08-10 2003-05-08 Cristina Costa Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
AU2002336417A1 (en) * 2001-08-31 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Methods of generating human cd4+ th1 cells
EP1425040A2 (en) * 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2002342299A1 (en) * 2001-10-31 2003-05-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Generation of use of tc1 and tc2 cells
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
EP1456652A4 (en) * 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc Agents that modulate immune cell activation and methods of use thereof
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
AP2005003294A0 (en) * 2002-09-27 2005-06-30 Tanox Inc Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
JP2006516117A (en) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド Treatment of non-malignant diseases or disorders using anti-ErbB2 antibodies
PT1570267E (en) * 2002-12-03 2012-01-03 Ucb Pharma Sa Assay for identifying antibody producing cells
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
DK1684805T3 (en) 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Use of antagonist anti-CD40 monoclonal antibodies to treat multiple myeloma
ES2346977T3 (en) 2003-11-04 2010-10-22 Novartis Vaccines And Diagnostics, Inc. THERAPY PROCEDURE FOR CANCERES THAT EXPRESS THE ANTIGEN CD40.
DE602004028270D1 (en) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic USE OF ANTAGONIST ANTI-CD40 ANTIBODIES FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
EP1844815B1 (en) * 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
ATE476991T1 (en) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic METHOD FOR TREATING SOLID TUMORS WITH EXPRESSION OF CD40 CELL SURFACE ANTIGEN
PL2805728T3 (en) 2003-12-23 2020-07-13 Genentech, Inc. Novel anti-IL 13 antibodies and uses thereof
ES2553987T3 (en) * 2003-12-25 2015-12-15 Kyowa Hakko Kirin Co., Ltd. Stable aqueous based pharmaceutical preparation containing antibody
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (en) * 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
ES2641815T3 (en) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Treatment for inflammatory diseases
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EP2096166A1 (en) * 2005-03-31 2009-09-02 Osaka University Method for production of antibody directed against cell membrane surface antigen epitope and assaying method
ES2429564T3 (en) 2005-05-18 2013-11-15 Novartis Ag Procedures for the diagnosis and treatment of diseases that have an autoimmune and / or inflammatory component
CN101237882B (en) 2005-05-26 2012-08-15 西雅图基因公司 Humanized anti-CD40 antibodies and their methods of use
EP1945260B1 (en) 2005-11-01 2012-10-24 Novartis AG Uses of anti-cd40 antibodies
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
CN101479375B (en) * 2006-05-03 2016-03-30 科罗拉多州立大学董事会 CD40 agonist antibody/type 1 interferon synergistic adjuvant combines, comprise the purposes of aforesaid binding substances and the therapeutical agent as enhancing cellular immunization thereof
EP2061812A4 (en) * 2006-08-22 2010-06-09 G2 Inflammation Pty Ltd Method for producing antibodies
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
JP2010527916A (en) * 2007-04-23 2010-08-19 ワイス・エルエルシー Methods and compositions for treating IL-13 related disorders and methods for monitoring the treatment
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
EP2215247B1 (en) * 2007-11-13 2014-09-24 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
DK3903829T3 (en) 2009-02-13 2023-06-26 Immunomedics Inc IMMUNE CONJUGATES WITH AN INTRACELLULAR CLEAVABLE BOND
CN102471383B (en) * 2009-08-04 2014-09-17 霍夫曼-拉罗奇有限公司 Beta Cell Marker Antibody
IN2012DN01663A (en) 2009-09-16 2015-06-05 Immunomedics Inc
JO3437B1 (en) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd Improved anti human Fraktalkine antibodies and uses thereof
WO2011063198A2 (en) 2009-11-20 2011-05-26 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
EP2385068A1 (en) * 2010-05-04 2011-11-09 Universitätsklinikum Hamburg-Eppendorf Polyclonal antiserum for use in immunotherapy
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
ES2734076T3 (en) 2011-02-17 2019-12-04 Kyowa Hakko Kirin Co Ltd Pharmaceutical preparation of highly concentrated anti-CD40 antibody
EP2683406B1 (en) * 2011-03-11 2019-05-08 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
US20140157443A1 (en) 2011-04-14 2014-06-05 St. Jude Children's Research Hospital Methods and compositions for detecting and modulating a novel mtor complex
ES2664619T3 (en) 2011-04-21 2018-04-20 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
CN103635488B (en) 2011-04-29 2016-12-14 埃派斯进有限公司 Anti-CD 40 antibodies and using method thereof
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US8609625B2 (en) * 2011-06-24 2013-12-17 Taipei Veterans General Hospital Method for enhancing immune response in the treatment of infectious and malignant diseases
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
KR102270618B1 (en) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 Anti-cd40 antibodies and methods of use
HUE057977T2 (en) 2012-12-13 2022-06-28 Immunomedics Inc Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
WO2014099636A1 (en) * 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
CA3174012A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
KR102373930B1 (en) 2013-09-13 2022-03-11 제넨테크, 인크. Methods and compositions comprising purified recombinant polypeptides
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
MX2016010683A (en) 2014-02-21 2017-05-11 Ibc Pharmaceuticals Inc Disease therapy by inducing immune response to trop-2 expressing cells.
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
EP3113796A1 (en) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
PL3204018T3 (en) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
EP3229586A4 (en) 2014-12-10 2018-10-24 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
RS59935B1 (en) 2015-05-29 2020-03-31 Abbvie Inc Anti-cd40 antibodies and uses thereof
ES2953441T3 (en) 2015-06-25 2023-11-13 Immunomedics Inc Combination of anti-hla-dr or anti-Trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP4129327A1 (en) 2015-08-28 2023-02-08 Amunix Pharmaceuticals, Inc. Chimeric polypeptide assembly and methods of making and using the same
CN116063481A (en) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 Humanized anti-CD 40 antibodies and uses thereof
KR20180054837A (en) 2015-09-30 2018-05-24 얀센 바이오테크 인코포레이티드 Functional antibodies specifically binding to human CD40 and methods of use
AU2016355569B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc CTLA4 binders
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
KR20180083418A (en) 2015-11-18 2018-07-20 머크 샤프 앤드 돔 코포레이션 PD1 / CTLA4 binding agent
CN108778301A (en) 2016-03-10 2018-11-09 永恒生物科技股份有限公司 The method for treating solid tumor or lymthoma by conjoint therapy
CN116059351A (en) 2016-04-18 2023-05-05 塞德斯医疗公司 Agonistic antibodies that bind human CD40 and uses thereof
US11365256B2 (en) 2016-06-08 2022-06-21 Xencor, Inc. Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases
US11905331B2 (en) 2016-11-11 2024-02-20 Kumho Ht, Inc. Antibody binding specifically to CD40 and use thereof
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020070288A1 (en) 2018-10-05 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
JPWO2022239720A1 (en) 2021-05-10 2022-11-17
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN114231551B (en) * 2021-12-24 2023-09-29 云南大学 Application of protein in promoting apoptosis of insect lymphocytes and/or preventing and controlling pests
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013981A1 (en) * 1990-03-15 1991-09-19 Basf Aktiengesellschaft New protein, its manufacture and use
WO1992000092A1 (en) * 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand for cd28 receptor on b cells and methods

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355023A (en) * 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4689299A (en) * 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
EP0138854B1 (en) * 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4727018A (en) * 1984-05-18 1988-02-23 Eichner Ronald D Immunoregulation of transplantable tissue
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5068223A (en) * 1985-09-09 1991-11-26 Board Of Regents, University Of Texas System Hydrophobic peptide esters and amides
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
IL82841A (en) 1986-06-13 1992-11-15 Oncogen Ligands and in vitro methods for augmenting b-cell proliferation
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
EP0434879A1 (en) * 1989-12-14 1991-07-03 Schering-Plough Method of making factor dependent human B cell lines
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
DE69226871T3 (en) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A receptor, fusion proteins containing it and their use
ATE274055T1 (en) 1991-10-25 2004-09-15 Immunex Corp NEW CYTOKINE
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
JP4157160B2 (en) * 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド Methods for the preparation of modified antibody variable regions
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
WO1994001457A1 (en) 1992-07-07 1994-01-20 Fish Eleanor N Interferon receptor binding peptides
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
ATE339451T1 (en) 1992-07-09 2006-10-15 Novartis Vaccines & Diagnostic ANTAGONIST MONOCLONAL ANTIBODIES TO HUMAN CD40
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
JP3675819B2 (en) * 1993-10-01 2005-07-27 イミュネックス・コーポレーション Antibody against CD40
ES2222463T3 (en) 1993-12-23 2005-02-01 Immunex Corporation USE OF MONOCLONAL ANTIBODIES OR SOLUBLE OLIGOMERIC LIGHTS IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE PREVENTION OR TREATMENT OF NEOPLASICAL DISORDERS.
AU4158396A (en) * 1994-11-10 1996-06-06 Dana-Farber Cancer Institute Methods for inhibiting graft versus host disease in bone marrow transplantation
US5916560A (en) 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
EP1115423A1 (en) 1998-09-21 2001-07-18 Genetics Institute, Inc. Methods of downmodulating the immune response to therapeutic proteins
WO2001024823A1 (en) 1999-10-04 2001-04-12 Chiron Corporation Cd40 antagonist for treating psoriasis
WO2001034649A2 (en) 1999-11-09 2001-05-17 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
CN101508734A (en) 2001-04-27 2009-08-19 协和发酵麒麟株式会社 Anti-CD40 monoclonal antibody
KR101200188B1 (en) 2003-12-25 2012-11-13 교와 핫꼬 기린 가부시키가이샤 Mutants of anti-cd40 antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013981A1 (en) * 1990-03-15 1991-09-19 Basf Aktiengesellschaft New protein, its manufacture and use
WO1992000092A1 (en) * 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand for cd28 receptor on b cells and methods

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J. KWEKKEBOOM ET AL.: "CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells.", IMMUNOLOGY, vol. 79, no. 3, 1993, OXFORD, GB, pages 439 - 444, XP002029781 *
K. JANSEN ET AL.: "Expression of human recombinant CD23 in insect cells.", JOURNAL OF RECEPTOR RESEARCH, vol. 11, no. 1-4, 1991, NEW YORK, USA, pages 507 - 520, XP001007769 *
M. DE BOER ET AL.: "Functional characterization of a novel anti-B7 monoclonal antibody.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 22, no. 12, December 1992 (1992-12-01), WEINHEIM, GERMANY, pages 3071 - 3075, XP001007758, DOI: doi:10.1002/eji.1830221207 *
M. DE BOER ET AL.: "Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 152, no. 1, 31 July 1992 (1992-07-31), AMSTERDAM, THE NETHERLANDS, pages 15 - 23, XP002108669, DOI: doi:10.1016/0022-1759(92)90084-7 *
N. WEBB ET AL.: "Cell-surface expression and purification of human CD4 produced in baculovirus-infected insect cells.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 86, no. 20, October 1989 (1989-10-01), WASHINGTON DC, USA, pages 7731 - 7735, XP000070875, DOI: doi:10.1073/pnas.86.20.7731 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828396B2 (en) 2010-11-15 2014-09-09 Novartis Ag Silent Fc variants of anti-CD40 antibodies

Also Published As

Publication number Publication date
US7361345B2 (en) 2008-04-22
PT945465E (en) 2007-01-31
JP2003119153A (en) 2003-04-23
JP2010215631A (en) 2010-09-30
US5677165A (en) 1997-10-14
JP2006348037A (en) 2006-12-28
CA2125472A1 (en) 1994-01-20
JP3514759B2 (en) 2004-03-31
JPH07509359A (en) 1995-10-19
JP2007145861A (en) 2007-06-14
US5869050A (en) 1999-02-09
US7790166B2 (en) 2010-09-07
JP2003081871A (en) 2003-03-19
US6056959A (en) 2000-05-02
US20020106371A1 (en) 2002-08-08
CA2125472C (en) 2011-02-01
US20090130095A1 (en) 2009-05-21
JP2008173133A (en) 2008-07-31
US5397703A (en) 1995-03-14
US6315998B1 (en) 2001-11-13
US6899879B2 (en) 2005-05-31
US20050169923A1 (en) 2005-08-04
WO1994001547A2 (en) 1994-01-20
JP2008260771A (en) 2008-10-30
US6004552A (en) 1999-12-21

Similar Documents

Publication Publication Date Title
WO1994001547A3 (en) A method for generation of antibodies to cell surface molecules
Nezlin The immunoglobulins: structure and function
EP1834671A3 (en) A method for generation of antibodies to cell surface molecules
Warner et al. Bone marrow graft rejection as a function of antibody-directed natural killer cells.
EP0722463A4 (en) Methods and composition for the modulation of host immune response to allergens
AU8727291A (en) Bispecific antibodies, method of production, and uses thereof
CA2137638A1 (en) Anti Gangliosides Monoclonal Antibodies and Their Use in the Specific Active Immunotherapy of Malignant Tumors
EP0499176A3 (en) Monoclonal antibodies against human pancreatic islet cells
EP1161955A3 (en) Induction of immunological tolerance for graft transplantation by the use of humanized non-depleting anti-cd4 antibodies in combination with specific donor bone marrow cells
Kroese et al. Monoclonal antibodies to rat B lymphocyte (sub-) populations
US5785966A (en) Inhibition of human xenogenic or allogenic antibodies to reduce xenograft or allograft rejection in human recipients
Dennert et al. Induction of bone marrow allograft rejection and hybrid resistance in nonresponder recipients by antibody: is there evidence for a dual receptor interaction in acute marrow graft rejection?
PL314414A1 (en) Antiidiotypic antibodies capable to induce an immunological response in respect to the receptor of epidermis growth factor
FI20095269A (en) Human endothelial cell molecule affecting the binding of lymphocytes
Thierfelder et al. Immunosuppression by Fc region‐mismatched anti‐T cell antibody treatment
Mosmann et al. The high background immune reactivity of mice to polymorphic determinants on xenogeneic erythrocytes: theoretical and practical implications.
Kremmer et al. Induction and suppression of anti-antibodies to syngeneic T cell-binding antibodies in mice
EP0380018A3 (en) Rat monoclonal antibodies directed against human antigens and processes for preparation thereof
WO1987007302A3 (en) MONOCLONAL ANTIBODIES TO HUMAN LYMPHOCYTE IgE RECEPTORS, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KITS FOR USING SUCH ANTIBODIES
De Boer et al. Method for generation of antibodies to cell surface molecules
Mateo et al. A different method for obtaining an engineered murine antibody, that recognizes epidermal growth factor receptor, with reduced immunogenicity
Suzan et al. The 5936 Ig‐Idiotype (s): Genetic Linkage to Ig‐CH Loci, T‐Cell Dependence of Synthesis and Possible Specificities
Mysliwietz et al. Long‐lasting unresponsiveness to polyclonal T cell‐binding immunoglobulins
STRoNG et al. Anti-idiotype antibody in the primate
GRONOWICZ et al. Quantity and Quality of Anti‐Hapten Antibodies in Normal and in T Cell‐Deprived Mice Studied at the Cellular Level

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2125472

Country of ref document: CA

Ref document number: 1993917032

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 1993917032

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993917032

Country of ref document: EP